Clinical Trial

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 post-HCT through Month 9 post-HCT.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2026-08-01 -> 2027-03-06 2026-08-11
minor Completion pushed: 2026-08-01 -> 2027-03-06 2026-08-11
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-19
notable Enrollment reduced: 224 -> 84 participants 2026-05-19
Trial Details
NCT Number NCT05683457
Lead Sponsor ModernaTX, Inc.
Conditions Cytomegalovirus Infection
Enrollment 84 participants
Start Date 2023-04-05
Primary Completion 2027-03-06 (estimated)
Study Completion 2027-03-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-10